featured
Sintilimab vs Placebo Combined With Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic ESCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BMJ: British Medical Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
BMJ 2022 Apr 19;377(xx)e068714, Z Lu, J Wang, Y Shu, L Liu, L Kong, L Yang, B Wang, G Sun, Y Ji, G Cao, H Liu, T Cui, N Li, W Qiu, G Li, X Hou, H Luo, L Xue, Y Zhang, W Yue, Z Liu, X Wang, S Gao, Y Pan, MP Galais, A Zaanan, Z Ma, H Li, Y Wang, L ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.